Trefoil Therapeutics' Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting
Additional data from the STORM study demonstrate vision quality to be a major driver of the patient decision to undergo surgerySAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics, a clinical-stage biotechnology company focused on developing novel new therapeutic agents to treat corneal diseases, today announced that TT...
Source: pharmiweb.com
